Skip to main content

Table 1 Demographic and baseline characteristics of patients between Ludangshen and placebo group

From: Ludangshen oral liquid for treatment of convalescent COVID-19 patients: a randomized, double-blind, placebo-controlled multicenter trial

Characteristics Ludangshen (n = 99) Placebo (n = 98) t/χ2/Z P value
Male (n, %) 28 (28.3) 33 (33.7) 0.747 0.387
Age (n, %)    − 0.191 0.848
 ≤ 30 9 (9.1) 5 (5.1)   
 31–40 16 (16.2) 23 (23.5)   
 41–50 23 (23.2) 21 (21.4)   
 51–60 25 (25.3) 18 (18.4)   
 ≥ 61 26 (26.3) 31 (31.6)   
BMI (Mean ± SD) 22.7 ± 2.86 23.7 ± 2.97 − 2.236 0.021
Smoking (n, %) 5 (5.0) 9 (9.2) 1.138 0.251
Drinking (n, %) 4 (4.0) 9 (9.2) 2.168 0.141
Temperature (Median, IQR) 36.5 (36.3–36.5) 36.5 (36.3–36.5) − 0.048 0.962
SBP (Mean ± SD) 123.4 ± 11.2 124.2 ± 11.7 − 0.512 0.609
DBP (Median, IQR) 79 (73–81) 76 (70–80.25) − 0.799 0.424
Breathing (Median, IQR) 18 (18–19) 18 (18–19) − 0.434 0.664
Resting heart rate (Median, IQR) 80 (75–86) 79.5 (75–86) − 0.498 0.625
Clinical classification (n, %)    − 0.296 0.767
 Mild cases 10 (10.1) 7 (7.1)   
 Moderate cases 77 (77.8) 80 (81.6)   
 Severe cases 11 (11.1) 11 (11.2)   
 Critical cases 1 (1.0) 0 (0.0)   
CT imaging (n, %)    0.359 0.549
 Normal 19 (19.2) 22 (22.5)   
 Abnormal 80 (80.8) 76 (77.6)   
Blood routine (n, %)    1.221 0.269
 Normal 99 (100.0) 94 (95.9)   
 Abnormal 0 (0.0) 1 (1.0)   
Allergy history (n, %) 16 (16.3) 14 (14.3) 0.133 0.737
Comorbidities (n, %) 25 (25.3) 27 (27.6) 0.166 0.683
Initial symptoms (n, %)     
 Fatigue 94 (94.9) 90 (91.8)
 Anorexia 68 (68.7) 70 (71.4)
 Distention 43 (43.4) 34 (34.7)
 Loose stools 48 (48.5) 52 (53.1)
 Shortness of breath 50 (50.5) 50 (51.0)
Concomitant medication (n, %) 13 (13.1) 15 (15.3) 0.217 0.641
Hospitalization length (Median, IQR) 19 (11–28) 18 (10.75–26.5) − 0.23 0.818
Discharge length (Median, IQR) 71 (59–81) 69.5 (50–80) − 0.61 0.542
  1. BMI body mass index, SD standard derivation, IQR interquartile range, SBP systolic blood pressure, DBP diastolic blood pressure